NasdaqCM - Nasdaq Real Time Price ? USD bioAffinity Technologies, Inc. (BIAF) Follow Compare 1.3100 -0.0200 (-1.50%) At close: November 15 at 4:00 PM EST 1.3700 +0.06 (+4.58%) After hours: November 15 at 5:21 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 SAN ANTONIO, November 14, 2024--bioAffinity Technologies releases financial results for the three months ended September 30, 2024. Business Wire ? 3 days ago BIAF -1.50% BIAFW bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development SAN ANTONIO, November 04, 2024--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to spearhead product development. Business Wire ? 13 days ago BIAF -1.50% BIAFW bioAffinity Technologies Announces Award of Japanese Patent for CyPath? Lung SAN ANTONIO, October 30, 2024--bioAffinity Technologies receives a Japanese patent for the method behind the CyPath? Lung diagnostic test for early-stage lung cancer. Business Wire ? 18 days ago BIAF -1.50% BIAFW WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock at a price of $1.30 per share and concurrent pri PR Newswire ? 27 days ago BIAF -1.50% BIAFW bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement SAN ANTONIO, October 21, 2024--bioAffinity Technologies announces closing of $2.6 million registered direct offering and concurrent private placement Business Wire ? 27 days ago BIAF -1.50% BIAFW WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that– bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has entered into a securities purchase agreement with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock in a registered direct offering at a price of $1.30 per share PR Newswire ? 30 days ago BIAF -1.50% BIAFW bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement SAN ANTONIO, October 18, 2024--bioAffinity Technologies announces pricing of $2.66 million registered direct offering and concurrent private placement. Business Wire ? 30 days ago BIAF -1.50% BIAFW bioAffinity’s CyPath? Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines SAN ANTONIO, October 16, 2024--bioAffinity VP served on expert panel to update flow cytometry guidelines for unique biological samples like sputum used in CyPath? Lung. Business Wire ? last month BIAF -1.50% BIAFW bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer SAN ANTONIO, October 10, 2024--bioAffinity Technologies names J. Michael Edwards as Chief Financial Officer. Business Wire ? last month BIAF -1.50% BIAFW bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath? Lung Test SAN ANTONIO, October 09, 2024--bioAffinity Technologies' CyPath? Lung test will be added to the Federal Supply Schedule to help veterans and active military at risk for lung cancer. Business Wire ? last month BIAF -1.50% BIAFW Peer-Reviewed Study: bioAffinity Technologies’ CyPath? Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis SAN ANTONIO, Texas, September 18, 2024--Study demonstrates how CyPath Lung diagnostic test for lung cancer can significantly reduce healthcare costs for both public and private insurers. Business Wire ? last month BIAF -1.50% BIAFW bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO SAN ANTONIO, August 23, 2024--J. Michael Edwards replaces Michael Dougherty as bioAffinity CFO; Dougherty is leaving for a position in the energy sector in the Pacific Northwest. Business Wire ? 2 months ago BIAF -1.50% BIAFW bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath? Lung Sales SAN ANTONIO, Texas, August 14, 2024--bioAffinity Technologies reports financial results and operational highlights for the quarter ended June 30, 2024. Business Wire ? 3 months ago BIAF -1.50% BIAFW bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million SAN ANTONIO, August 05, 2024--bioAffinity Technologies announces closing of registered direct offering, private placement and warrant inducement for gross proceeds of $1.75 million Business Wire ? 3 months ago BIAF -1.50% BIAFW WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF) (the "Company") has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 1,041,667 of the Company's shares of common stock (the "Existing Warrants"). In consideration for the immediate exercise in full of the Existing Warrants for gro PR Newswire ? 3 months ago BIAF -1.50% BIAFW bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million SAN ANTONIO, August 02, 2024--bioAffinity Technologies announces pricing of registered direct offering and concurrent private placement and warrant inducement. Business Wire ? 3 months ago BIAF -1.50% BIAFW Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money? show, a sponsored program on Bloomberg TV, ... ACCESSWIRE ? 4 months ago BIAF -1.50% BIAFW BTCY bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath? Lung SAN ANTONIO, July 09, 2024--bioAffinity Technologies raises the 2024 full-year forecast for sales of CyPath Lung, a noninvasive test for lung cancer, by 85%. Business Wire ? 4 months ago BIAF -1.50% BIAFW BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money? show, a sponsored program on Bloomberg TV, this ... ACCESSWIRE ? 4 months ago BIVI BIAF -1.50% BIAFW bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath? Lung Tests SAN ANTONIO, June 12, 2024--bioAffinity Technologies reports a 139% growth in the number of pulmonology practices and physicians ordering CyPath Lung for their patients. Business Wire ? 5 months ago BIAF -1.50% BIAFW Performance Overview Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return BIAF S&P 500 YTD -10.94% +23.08% 1-Year -9.09% +30.58% 3-Year -84.40% +47.99%
